184 related articles for article (PubMed ID: 7534101)
1. Clinical trials referral resource. Prostate cancer.
Cheson BD; Kaplan RS; Phillips PH
Oncology (Williston Park); 1994 Dec; 8(12):35-6. PubMed ID: 7534101
[No Abstract] [Full Text] [Related]
2. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
3. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
[TBL] [Abstract][Full Text] [Related]
4. Management of newly diagnosed metastatic carcinoma of the prostate.
Elder JS; Catalona WJ
Urol Clin North Am; 1984 May; 11(2):283-95. PubMed ID: 6428022
[TBL] [Abstract][Full Text] [Related]
5. Flutamide for prostate cancer.
Med Lett Drugs Ther; 1989 Jul; 31(797):72. PubMed ID: 2501635
[No Abstract] [Full Text] [Related]
6. [Oncologic after-care of patients with prostate cancer].
Friedrich A; Glass W
Z Urol Nephrol; 1986 Apr; 79(5):269-75. PubMed ID: 2426869
[TBL] [Abstract][Full Text] [Related]
7. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer metastasis to supraclavicular lymph node.
Hobdy EM; Shafi NQ; Kummar S
Clin Adv Hematol Oncol; 2004 Apr; 2(4):223-4; discussion 224. PubMed ID: 16163185
[No Abstract] [Full Text] [Related]
9. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
10. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
Solomon MH; McHugh TA; Dorr RP; Lee F; Siders DB
Clin Invest Med; 1993 Dec; 16(6):532-8. PubMed ID: 8013157
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life among patients with metastatic prostate cancer.
Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
[TBL] [Abstract][Full Text] [Related]
12. Difficult diagnostic and therapeutic cases: CASE 3. presentation of prostate cancer with cervical adenopathy.
Gaur S; Aish LS; Oo TH
J Clin Oncol; 2004 Mar; 22(5):957-8. PubMed ID: 14990654
[No Abstract] [Full Text] [Related]
13. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
15. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
16. [Current status of therapy of prostate cancer].
Nagel R; Leistenschneider W; Knipper A
Helv Chir Acta; 1983 Jun; 50(3):321-35. PubMed ID: 6195128
[No Abstract] [Full Text] [Related]
17. [Prostatic adenocarcinoma. III. Results of radical treatment. Review of the literature].
Valls Fontanals A; Panadés Nigorra G; Ballester Moll T
Actas Urol Esp; 1985; 9(2):121-6. PubMed ID: 3893054
[No Abstract] [Full Text] [Related]
18. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
[No Abstract] [Full Text] [Related]
19. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Debruyne FM; Witjes WP
Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
